We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Observational Study Adds Pressure to FDA to Halt Trial of Avandia
Observational Study Adds Pressure to FDA to Halt Trial of Avandia
June 23, 2010
A new observational study co-authored by outspoken FDA drug reviewer David Graham has found that GlaxoSmithKline’s (GSK) drug Avandia increased the risk of stroke, heart failure and death when compared with Takeda’s diabetes treatment Actos.